Roche podcast with Timmo Grimmer compelling no? He joins Anavex SAB and the following day appears on a podcast recapping CTAD, presented by Roche, and illuminates the efficacy of Anavex 273.
if Anavex has the data that will get FDA's blessings, do you think it will be ready to be bought out by Roche at this stage?
I would hope not! If AVXL thinks it has the goods, it doesn't need to even consider the buyout avenue until the investment is fully de-risked following regulatory approvals for Blarcamesine after which AVXL will have maximum leverage. I still think the correct answer is for AVXL to find the correct partner(s) for purposes of worldwide sales and distribution. No need for a buyout ever unless the price is too overwhelming to turn down.
I believe we are undervalued if we are being looked at by big pharma. We had stellar results and we are under 30 bucks a share.there is a reason that millions are crossing our southern border.they may have heard about the phase 3 results.